Left behind? Drug discovery in extensive-stage small-cell lung cancer

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages 93-95

  Riess, Jonathan W ^a   Lara Jr , Primo N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amrubicin; Chemotherapy; Clinical trials; Developmental therapeutics; Small cell lung cancer

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DESIPRAMINE; DOXORUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IRINOTECAN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1; TOPOTECAN; VINCRISTINE;

ADVERSE OUTCOME; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); EXTENSIVE STAGE SMALL CELL LUNG CANCER; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; DRUG DEVELOPMENT; LUNG NEOPLASMS; PATHOLOGY; SMALL CELL LUNG CARCINOMA;

DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; SMALL CELL LUNG CARCINOMA;

EID: 84894180448     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.12.010     Document Type: Note

References (20)

1. R.L. Souhami, S.G. Spiro, and R.M. Rudd et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy J Natl Cancer Inst 89 1997 577 580
2. D.J. Girling Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party Lancet 348 1996 563 566
3. R. Govindan, N. Page, and D. Morgensztern et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 2006 4539 4544
4. J.P. Pierce, K. Messer, M.M. White, D.W. Cowling, and D.P. Thomas Prevalence of heavy smoking in California and the United States, 1965-2007 JAMA 305 2011 1106 1112
5. T. Li, H.J. Kung, P.C. Mack, and D.R. Gandara Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies J Clin Oncol 31 2013 1039 1049
6. G.P. Kalemkerian, W. Akerley, and P. Bogner et al. Small cell lung cancer J Natl Compr Canc Netw 11 2013 78 98
7. P.N. Lara Jr.; R. Natale, and J. Crowley et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol 27 2009 2530 2535
8. K. Noda, Y. Nishiwaki, and M. Kawahara et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 2002 85 91
9. M. Neubauer, J. Schwartz, and J. Caracandas et al. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years J Clin Oncol 22 2004 1872 1877
10. H.B. Niell, J.E. Herndon 2nd, and A.A. Miller et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732 J Clin Oncol 23 2005 3752 3759
11. M.A. Socinski, E.F. Smit, and P. Lorigan et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer J Clin Oncol 27 2009 4787 4792
12. M.C. Pietanza, K. Kadota, and K. Huberman et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker Clin Cancer Res 18 2012 1138 1145
13. J. von Pawel, J.H. Schiller, and F.A. Shepherd et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 1999 658 667
14. R. Jotte, J. Von Pawel, and D.R. Spigel et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC) J Clin Oncol 29 suppl 2011 (abstract 7000)
15. M. Peifer, L. Fernandez-Cuesta, and M.L. Sos et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Nat Genet 44 2012 1104 1110
16. I. Fichtner, J. Rolff, and R. Soong et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers Clin Cancer Res 14 2008 6456 6468
17. J.M. Hou, M.G. Krebs, and L. Lancashire et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer J Clin Oncol 30 2012 525 532
18. M. Joshi, A. Ayoola, and C.P. Belani Small-cell lung cancer: an update on targeted therapies Adv Exp Med Biol 779 2013 385 404
19. M.L. Sos, F. Dietlein, and M. Peifer et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer Proc Natl Acad Sci U S A 109 2012 17034 17039
20. N.S. Jahchan, J.T. Dudley, and P.K. Mazur et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors Cancer discovery 3 2013 1364 1377